Some 87 percent of
TNBC patients with stages 1, 2, and 3 triple-negative breast cancer treated
with current chemotherapy survived disease-free, according to the BEATRICE
phase III trial presented today at the San Antonio Breast Cancer Symposium.
The trial actually was
designed to determine whether Avastin (bevacizumab) plus chemotherapy was more
effective than chemotherapy alone. There
was no significant statistical difference between the two groups.
Such positive results are becoming common for TNBC, said Kent Osborne, M.D., director of
the Dan L. Duncan Cancer and the Lester and Sue Smith Breast Center at
Baylor College of Medicine in Houston, Texas.
“We’re seeing this across the board.”
This is additional evidence that
newer chemotherapy regimens, including taxanes, are effective against TNBC, said
David
Cameron, M.D.,
professor of oncology at Edinburgh University in Scotland and lead author of
the paper. “It’s a result of triple-negative patients getting the highest standard
of care.
All women enrolled in the study had three chemotherapy
options:
• Taxanes alones (at least 4
cycles)
• Anthracyclines alone (at least
4 cycles)
•Anthracuclines plus taxane (3
to 4 cycles each)
The data have not yet been reported based on specific stages,
so this average includes a broad range of patients. Those with earlier stage disease will no doubt see
even better results. The results were
reported at a median follow-up of 32 months.
Read more about TNBC in my book, Surviving Triple-Negative Breast Cancer.
Please consider a donation to Positives About Negative to keep this site going. This work is entirely supported by readers. Just click on the Donate button in the right of the page. Thank you!
No comments:
Post a Comment